J&J Janssen: Macitentan and Tadalafil Up Pulmonary Hemodynamics versus Monotherapy in PAH

 Study findings presented during the American College of Cardiology's 72nd Annual Scientific Session & Expo Together With World Heart Federation's World Congress of Cardiology

European Society of Cardiology/European Respiratory Society (ESC/ERS) PH guidelines recommend initial dual combination therapy with macitentan and tadalafil for PAH patients without cardiopulmonary comorbidities

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 3 A DUE study (NCT03904693), which showed an investigational once-daily, single tablet combination therapy, also known as fixed dose combination, of macitentan 10 mg and tadalafil 40 mg (M/T STCT), significantly improved pulmonary hemodynamics (blood flow through pulmonary blood vessels) versus macitentan and tadalafil monotherapies in pulmonary arterial hypertension (PAH) patients with World Health Organization (WHO) functional class (FC) II or III.1 The data were presented today as a Late-Breaking Clinical Trial presentation during the American College of Cardiology's 72nd Annual Scientific Session & Expo Together With World Heart Federation's World Congress of Cardiology.

https://www.prnewswire.com/news-releases/late-breaking-phase-3-a-due-data-show-investigational-single-tablet-combination-therapy-of-macitentan-and-tadalafil-significantly-improves-pulmonary-hemodynamics-versus-monotherapy-in-patients-with-pulmonary-arterial-hypertension--301762855.html